B cells have generally been considered to be only peripherally involved in the pathogenesis of multiple sclerosis. More recently, however, drug agents that deplete B cells have been shown to profoundly impact multiple sclerosis, greatly improving outcomes for patients affected by this autoimmune disease. Nonetheless, B-cell involvement in multiple sclerosis, for some, remains controversial.